{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T20:10:28Z","timestamp":1771791028839,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.resinv.2023.12.006","type":"journal-article","created":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T11:03:17Z","timestamp":1704625397000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Carbapenem vs. non-carbapenem antibiotics for ventilator-associated pneumonia: A systematic review with meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Hisayuki","family":"Shuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-1661","authenticated-orcid":false,"given":"Kosaku","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Shime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2023.12.006_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1473-3099(13)70081-1","article-title":"Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies","volume":"13","author":"Melsen","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcrc.2007.08.007","article-title":"Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis","volume":"23","author":"Kuti","year":"2008","journal-title":"J Crit Care"},{"key":"10.1016\/j.resinv.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.resinv.2023.12.006_bib5","series-title":"Guidelines for the prevention and control of carbapenem-resistant enterobacteriaceae, acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities","article-title":"WHO guidelines approved by the guidelines review committee","year":"2017"},{"key":"10.1016\/j.resinv.2023.12.006_bib6","article-title":"Antibiotics for ventilator-associated pneumonia","volume":"10","author":"Arthur","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.resinv.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.12.006_bib9","first-page":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"Suppl 2","key":"10.1016\/j.resinv.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/426192","article-title":"Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial","volume":"40","author":"Shorr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"R\u00e9a-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.resinv.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2023.12.006_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.resinv.2023.12.006_bib18","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.chest.2020.10.039","article-title":"Carbapenem antibiotics for the empiric treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"159","author":"Howatt","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2023.12.006_bib21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jiac.2022.04.012","article-title":"Methicillin-resistant Staphylococcus aureus among elderly patients with community-acquired pneumonia","volume":"28","author":"Goto","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","article-title":"Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia","volume":"180","author":"Jones","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.resinv.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/jtm\/taw102","article-title":"The ecology of extended-spectrum \u03b2-lactamases (ESBLs) in the developed world","volume":"24","author":"Doi","year":"2017","journal-title":"J Trav Med"},{"key":"10.1016\/j.resinv.2023.12.006_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.resinv.2023.12.006_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106278","article-title":"Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)","volume":"57","author":"Johnson","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.resinv.2023.12.006_bib26","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Espa\u00f1ola Quimioter"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523001144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523001144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:31Z","timestamp":1761950011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534523001144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2212534523001144"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2023.12.006","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbapenem vs. non-carbapenem antibiotics for ventilator-associated pneumonia: A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}